Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Roche has found redemption in a precision medicine approach following an earlier Tecentriq trial flop in a broader bladder cancer population. | Roche has found redemption in a precision medicine ...

Oncology sales comprise more than 25% of Pfizer’s total revenues. Its oncology revenues grew 9% in the first half of 2025, ...

PD-1 inhibitors are projected to dominate future drug sales. Immuno-oncology therapies, particularly the PD-(L)1 class, have revolutionized cancer ca ...

Meanwhile, AstraZeneca recently got approval in Japan for its cancer immunotherapy combination of PD-L1 inhibitor Imfinzi (durvalumab) and CTLA4 inhibitor Imjudo (tremelimumab) as a first-line ...

In addition to AstraZeneca’s lung cancer data, a number of companies presented data on KRAS inhibitors, a target once thought to be undruggable, that’s offering tremendous promise in treating ...

A medical crisis is reshaping the cancer treatment landscape. Young adults under 50 are experiencing unprecedented cancer rates, with aggressive tumors requiring innovative combination approaches that ...